EMA still wants 700 GVK-related drugs off the market

The European Medicines Agency has affirmed its January recommendation, calling for the suspension of more than 700 products tied to improprieties at a GVK Biosciences facility in India.

Ergomed snags a postmarketing firm with its eye on pharmacovigilance

U.K. CRO Ergomed is expanding its share of the postmarketing services business, buying a medical information firm that fields patient queries for drug companies.

Quintiles homes in on Asian biotech with its latest offering

Quintiles, the world's largest CRO, is targeting the growing number of small and midsize biotech companies in Asia, porting its bespoke offering to the region in hopes of partnering with the continent's up-and-coming drug developers.

Quintiles' founders bank $770M in secondary offering

A group of Quintiles shareholders including the CRO's founder made about $770 million in a secondary stock offering, selling a bulk of shares back to the company and cashing in on its success.

Quotient Clinical soars in its first year after a PE buyout

A year removed from taking a private equity buyout, U.K. CRO Quotient Clinical has watched demand for its services spike, the company said, plotting some major investments to keep the pace of growth.

InVentiv invests in compliance as regulations shift for real-world studies

CRO inVentiv Health is amping up its capacity in regulatory compliance to prepare for changes in European trial rules, unveiling a global database it claims can help sponsors avoid costly confusion.

WuXi posts another big quarter as it faces a big decision

WuXi PharmaTech, China's largest CRO, again boosted its revenue by double digits last quarter, keeping the pace of growth as it considers an offer to go private.

Patheon sells off its Mexican division for $34M

Contract drug developer Patheon has flipped its Mexican operations to Perrigo for $34 million in cash, shifting its focus to the U.S. and Europe.

Evotec brightens its outlook after $286M Sanofi deal

Evotec, a German company that straddles the line between CRO and biotech, rode its innovative model to revenue growth in the first quarter, raising its expectations for 2015 after signing an expansive deal with Sanofi.

Theorem expands in Europe with new supplies facility

U.S. CRO Theorem Clinical Research is investing in its overseas infrastructure, setting up a new clinical supplies facility in Germany to speed up trials on the continent.

QPS cuts the ribbon on a new lab for early-stage R&D

Global CRO QPS Holdings opened a new lab devoted to in vitro research, setting up shop in Fargo, ND, with eyes on early-stage partnerships.

WuXi weighs going private with a deal on the table

WuXi PharmaTech, China's largest CRO, is considering an offer that would take it private at a sizable premium, forming a committee of independent advisers as it plots its next move.

PRA posts a big quarter despite the bite of currency fluctuations

PRA Health Sciences shook off the effects of a surging dollar to pull off 7% revenue growth in the first quarter, kicking off the year with its largest ever backlog.

Biocon's planned CRO IPO could change the tone in India

Biocon, India's pre-eminent biotech company, is planning to spin out its in-house CRO in an Indian IPO, a move that shines a light on the country's evolving industry.

Catalent boosts its profits despite some flat revenue

Catalent came through with a big earnings boost last quarter, shaking off some deleterious currency fluctuations and cutting costs.

Canadian CRO JSS buys its way into India with latest deal

Montreal-headquartered CRO JSS Medical Research is reaching into India, buying out Max Neeman International as it expands around the globe.

Quintiles beefs up in bioanalytics ahead of Quest partnership

Awaiting the closure of a wide-ranging deal with Quest Diagnostics, Quintiles is expanding its capabilities in bioanalytics, opening a new outpost in Europe for lab tests.

AMRI swings to another loss despite big sales gains

Contract drug developer AMRI, on the mend after a series of setbacks, posted a 38% sales boost to start the year, but the costs of an ongoing transition dragged it into the red for yet another quarter.

Parexel trims its ambitions after a flat quarter

CRO giant Parexel posted flat revenue last quarter, paring back its full-year expectations in the face of currency headwinds and client delays.

Allergan picks CRO ImageIQ for bladder trial

Allergan has reached out to CRO ImageIQ to support its development of a new treatment for bladder disease, recruiting the imaging specialist to pitch in on a new clinical trial.